Published in Crit Rev Oncol Hematol on July 01, 2003
Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagn Pathol (2012) 0.92
HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker? Br J Cancer (2013) 0.91
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer (2007) 0.91
Sex hormone receptor levels in laryngeal carcinoma: a comparison between protein and RNA evaluations. Eur Arch Otorhinolaryngol (2008) 0.87
Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification. Acta Otorhinolaryngol Ital (2006) 0.86
Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol (2011) 0.86
S100A11 is a migration-related protein in laryngeal squamous cell carcinoma. Int J Med Sci (2013) 0.83
The epidemiology of laryngeal cancer in a country on the esophageal cancer belt. Indian J Otolaryngol Head Neck Surg (2009) 0.82
l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer. Transl Oncol (2012) 0.79
Association of OPN overexpression with tumor stage, differentiation, metastasis and tumor progression in human laryngeal squamous cell carcinoma. Int J Clin Exp Med (2015) 0.77
Factors predictive of outcome following primary total laryngectomy for advanced squamous cell carcinoma. Eur Arch Otorhinolaryngol (2013) 0.76
The prognostic significance of estrogen receptor β in head and neck squamous cell carcinoma. Oncol Lett (2016) 0.75
Lentivirus‑delivered nemo‑like kinase small interfering RNA inhibits laryngeal cancer cell proliferation in vitro. Mol Med Rep (2015) 0.75
Significance of Parafibromin Expression in Laryngeal Squamous Cell Carcinomas. J Pathol Transl Med (2016) 0.75
Laryngeal squamous cell cancer with late presentation of isolated liver metastasis on fluorodeoxyglucose positron emission tomography-computed tomography. Indian J Nucl Med (2016) 0.75
Expression of DNA topoisomerase II-α: Clinical significance in laryngeal carcinoma. Oncol Lett (2014) 0.75
Functional characterization of OPN in human laryngeal squamous cell carcinoma and its xenograft model in nude mice. Int J Clin Exp Med (2015) 0.75
Identification of key target genes and pathways in laryngeal carcinoma. Oncol Lett (2016) 0.75
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol (2007) 8.05
Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol (2008) 7.18
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med (2003) 2.76
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Incidence of uveal melanoma in Europe. Ophthalmology (2007) 2.30
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol (2010) 1.93
Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2012) 1.83
Major and minor salivary gland tumors. Crit Rev Oncol Hematol (2009) 1.77
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol (2013) 1.68
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol (2008) 1.65
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
Colon cancer. Crit Rev Oncol Hematol (2010) 1.62
Cholangiocarcinoma. Crit Rev Oncol Hematol (2008) 1.59
Glioblastoma in adults. Crit Rev Oncol Hematol (2008) 1.54
Ependymoma. Crit Rev Oncol Hematol (2007) 1.41
Cancer of the penis. Crit Rev Oncol Hematol (2005) 1.39
Preoperative concomitant hyperfractionated radiotherapy and gemcitabine for locally advanced rectal cancers: a phase I-II trial. Cancer J (2005) 1.38
Germ cell tumours of the testis. Crit Rev Oncol Hematol (2005) 1.37
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res (2006) 1.37
Adult acute myeloid leukaemia. Crit Rev Oncol Hematol (2004) 1.37
Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer (2008) 1.35
Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol (2003) 1.33
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
The cure of cancer: a European perspective. Eur J Cancer (2009) 1.31
Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study. Eur J Cancer (2006) 1.18
Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol (2004) 1.17
Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol (2007) 1.17
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures. Oral Oncol (2005) 1.16
The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori (2012) 1.15
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer (2009) 1.12
Survival in patients with uveal melanoma in Europe. Arch Ophthalmol (2008) 1.11
Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys (2004) 1.11
Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open (2013) 1.10
Cancer of the oropharynx. Crit Rev Oncol Hematol (2002) 1.09
Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol (2008) 1.08
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol (2009) 1.06
Comparative dosimetric evaluation of the simultaneous integrated boost with photon intensity modulation in head and neck cancer patients. Radiother Oncol (2003) 1.04
Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study. Int J Radiat Oncol Biol Phys (2005) 1.04
Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys (2003) 1.03
Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol (2007) 1.03
Oligodendroglioma. Crit Rev Oncol Hematol (2008) 1.01
Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope (2006) 1.00
Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res (2002) 1.00
Explaining gastric cancer survival differences among European countries. Int J Cancer (2004) 1.00
Major and minor salivary glands tumours. Crit Rev Oncol Hematol (2003) 0.99
Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol (2009) 0.99
Burn injury induces a change in T cell homeostasis affecting preferentially CD4+ T cells. J Leukoc Biol (2004) 0.99
Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev (2012) 0.97
Cancer of the nasopharynx. Crit Rev Oncol Hematol (2003) 0.97
An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health (2008) 0.97
Renal cancer. Crit Rev Oncol Hematol (2007) 0.96
Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev (2010) 0.95
Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys (2011) 0.94
Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. Int J Radiat Oncol Biol Phys (2010) 0.93
Childhood medulloblastoma. Crit Rev Oncol Hematol (2010) 0.92
Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am (2008) 0.92
Selective effect of burn injury on splenic CD11c(+) dendritic cells and CD8alpha(+)CD4(-)CD11c(+) dendritic cell subsets. Cell Mol Life Sci (2010) 0.92
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. Tumori (2005) 0.92
Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. Oral Oncol (2005) 0.91
Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach. Oral Oncol (2004) 0.91
Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Curr Opin Oncol (2013) 0.90
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology (2006) 0.90
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag (2007) 0.89
Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys (2003) 0.89
Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. Strahlenther Onkol (2003) 0.89
Colon cancer. Crit Rev Oncol Hematol (2004) 0.89
Clinical experience in breast irradiation with intensity modulated photon beams. Acta Oncol (2005) 0.89
Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys (2009) 0.87
Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol (2015) 0.87
Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. Int J Radiat Oncol Biol Phys (2005) 0.86
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol (2011) 0.86
Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr (2013) 0.86
EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res (2010) 0.86
Implications of a positive sentinel node in oral squamous cell carcinoma. Head Neck (2012) 0.85
Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol (2012) 0.85
Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer (2004) 0.85
Rectal cancer. Crit Rev Oncol Hematol (2008) 0.84
Organ and voice preservation in advanced laryngeal cancer. Acta Otolaryngol (2002) 0.83
T cells from burn-injured mice demonstrate a loss of sensitivity to glucocorticoids. Am J Physiol Endocrinol Metab (2010) 0.83
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule. Int J Radiat Oncol Biol Phys (2006) 0.83
The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab (2012) 0.83